Target intelligence / Profile preview

Glutathione synthetase (or Glutamate–cysteine ligase) (GSS (for Glutathione synthetase), GCL (for Glutamate–cysteine ligase))

Target
GSS (for Glutathione synthetase), GCL (for Glutamate–cysteine ligase)
Molecular classification
Enzyme, Ligase (for both GSS and GCL)
01

Overview

“Glutathione synthesis pathway enzymes” refer to the key enzymes responsible for the biosynthesis of glutathione, a tripeptide that serves as a major cellular antioxidant and detoxifying agent. The pathway comprises two main ATP-dependent enzymes: glutamate–cysteine ligase (which catalyzes the formation of gamma-glutamylcysteine from L-glutamate and L-cysteine), and glutathione synthetase (which catalyzes the subsequent condensation of gamma-glutamylcysteine with glycine to produce glutathione). Deficiencies or dysregulation of these enzymes are associated with a range of metabolic, neurological, and oxidative stress–related diseases. Pharmacological targeting of these enzymes alters glutathione availability, affecting redox balance and cell survival[2][3][4].

Other names
Glutathione synthaseGSH synthetasegamma-glutamylcysteine synthase (for GCL)gamma-glutamyl-L-cysteine:glycine ligase (for GSS)
02

Mechanism of action

Inhibition of enzyme activity decreases cellular glutathione, leading to increased susceptibility to oxidative stress and cell death Modulation of glutathione biosynthesis as a therapeutic approach for diseases with glutathione dysregulation

03

Biological functions

Glutathione biosynthesisAntioxidant defenseDetoxification of reactive oxygen species and xenobioticsMaintenance of cellular redox state
04

Disease associations

Metabolic disease (glutathione synthetase deficiency)Oxidative stress–related diseasesNeurodegenerative diseaseCancer
05

Safety considerations

Inhibition can result in glutathione depletion, causing hepatotoxicity, neurotoxicity, or increased risk of hemolysis and metabolic acidosis (notably with glutathione synthetase deficiency)
06

Interacting drugs

Buthionine sulfoximine (inhibitor of GCL)

1 more in the full profile.

07

Biomarkers

Glutathione levels in blood or tissue can serve as a biomarker for oxidative stress, metabolic status, and response to treatment

Beyond the preview

Go deeper on Glutathione synthetase (or Glutamate–cysteine ligase) (GSS (for Glutathione synthetase), GCL (for Glutamate–cysteine ligase)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutathione synthetase (or Glutamate–cysteine ligase) (GSS (for Glutathione synthetase), GCL (for Glutamate–cysteine ligase)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call